Ֆաբրիի հիվանդություն (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ֆաբրիի հիվանդություն" in Armenian language version.

refsWebsite

Global rank Armenian rank

27nih.gov

4^th place

3^rd place

21doi.org

2^nd place

4^th place

6semanticscholar.org

11^th place

428^th place

6europa.eu

68^th place

88^th place

5worldcat.org

5^th place

10^th place

3archive.org

6^th place

3web.archive.org

1^st place

3fda.gov

447^th place

244^th place

2zenodo.org

621^st place

1,041^st place

2fabrydisease.org

low place

2clinicaltrials.gov

5,225^th place

3,687^th place

1escholarship.org

1,523^rd place

2,188^th place

1harvard.edu

18^th place

38^th place

1oup.com

485^th place

273^rd place

1ucl.ac.uk

1,306^th place

876^th place

1npr.org

92^nd place

271^st place

1pharmatimes.com

low place

1drugs.com

399^th place

102^nd place

1oxfordmedicine.com

low place

1globenewswire.com

2,614^th place

8,091^st place

1eurekalert.org

3,538^th place

2,373^rd place

1uhnresearch.ca

low place

1fabrydiseasenews.com

low place

1handle.net

102^nd place

2,318^th place

1books.google.com

3^rd place

17^th place

1fiercebiotech.com

low place

archive.org

James, Berger & Elston 2006, էջ. 538 James, William D.; Berger, Timothy G.; Elston, Dirk (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
James, Berger & Elston 2006, էջեր. ^{&#91, Հղում աղբյուրներին&#93,} James, William D.; Berger, Timothy G.; Elston, Dirk (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 978-0-7216-2921-6.
Marchesoni, Cintia L.; Roa, Norma; Pardal, Ana María; Neumann, Pablo; Cáceres, Guillermo; Martínez, Pablo; Kisinovsky, Isaac; Bianchi, Silvia; Tarabuso, Ana Lía; Reisin, Ricardo C. (May 2010). «Misdiagnosis in Fabry disease». The Journal of Pediatrics. 156 (5): 828–31. doi:10.1016/j.jpeds.2010.02.012. PMID 20385321.

books.google.com

John Thorne Crissey; Lawrence C. Parish; Karl Holubar (2013). Historical Atlas of Dermatology and Dermatologists. CRC Press. էջ 179. ISBN 978-1-84214-100-7.

clinicaltrials.gov

«Search for interventional trials with Replagal and Fabrazyme on clinicaltrials.gov». Վերցված է 2022 թ․ մարտի 21-ին.
«Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease - Full Text View - ClinicalTrials.gov». clinicaltrials.gov. Վերցված է 2020 թ․ մայիսի 31-ին.

doi.org

Fabry, Joh (December 1898). «Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)» [A contribution to the knowledge of the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Archiv für Dermatologie und Syphilis (գերմաներեն). 43 (1): 187–200. doi:10.1007/bf01986897. S2CID 33956139.
Schiffmann, Raphael (2015). «Fabry disease». Neurocutaneous Syndromes. Handbook of Clinical Neurology. Vol. 132. էջեր 231–248. doi:10.1016/B978-0-444-62702-5.00017-2. ISBN 9780444627025. PMID 26564084.
Hoffmann, Bjoern; Beck, Michael; Sunder-Plassmann, Gere; Borsini, Walter; Ricci, Roberta; Mehta, Atul; FOS European, Investigators. (July 2007). «Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey». The Clinical Journal of Pain. 23 (6): 535–542. doi:10.1097/AJP.0b013e318074c986. PMID 17575495. S2CID 36215895.
Putko, Brendan N.; Wen, Kevin; Thompson, Richard B.; Mullen, John; Shanks, Miriam; Yogasundaram, Haran; Sergi, Consolato; Oudit, Gavin Y. (March 2015). «Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment». Heart Failure Reviews. 20 (2): 179–191. doi:10.1007/s10741-014-9452-9. ISSN 1573-7322. PMID 25030479. S2CID 11521278.
Akhtar, M. M.; Elliott, P. M. (2018 թ․ հունիսի 16). «Anderson-Fabry disease in heart failure». Biophysical Reviews. 10 (4): 1107–1119. doi:10.1007/s12551-018-0432-5. ISSN 1867-2450. PMC 6082315. PMID 29909504.
«Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two». Pediatric Rheumatology Online Journal. 15 (Suppl 2): 65. 2017 թ․ սեպտեմբերի 1. doi:10.1186/s12969-017-0186-9. PMC 5592437.
Karen, Julie K.; Hale, Elizabeth K.; Ma, Linglei (2005). «Angiokeratoma corporis diffusum (Fabry disease)». Dermatology Online Journal. 11 (4): 8. doi:10.5070/D30TT696NJ. PMID 16403380.
Šimčíková D, Heneberg P (December 2019). «Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases». Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC 6901466. PMID 31819097.
Perrot, Andreas; Osterziel, Karl Josef; Beck, Michael; Dietz, Rainer; Kampmann, Christoph (2002 թ․ նոյեմբերի 1). «Fabry Disease: Focus on Cardiac Manifestations and Molecular Mechanisms». Herz. 27 (7): 699–702. doi:10.1007/s00059-002-2429-9. PMID 12439642. S2CID 25962218.
Germain, Dominique P (2010). «Fabry disease». Orphanet Journal of Rare Diseases. 5 (1): 30. doi:10.1186/1750-1172-5-30. PMC 3009617. PMID 21092187.
Marchesoni, Cintia L.; Roa, Norma; Pardal, Ana María; Neumann, Pablo; Cáceres, Guillermo; Martínez, Pablo; Kisinovsky, Isaac; Bianchi, Silvia; Tarabuso, Ana Lía; Reisin, Ricardo C. (May 2010). «Misdiagnosis in Fabry disease». The Journal of Pediatrics. 156 (5): 828–31. doi:10.1016/j.jpeds.2010.02.012. PMID 20385321.
Hagège, Albert; Réant, Patricia; Habib, Gilbert; Damy, Thibaud; Barone-Rochette, Gilles; Soulat, Gilles; Donal, Erwan; Germain, Dominique P. (April 2019). «Fabry disease in cardiology practice: Literature review and expert point of view». Archives of Cardiovascular Diseases (անգլերեն). 112 (4): 278–287. doi:10.1016/j.acvd.2019.01.002. PMID 30826269.
Baig, S; Vijapurapu, R; Alharbi, F; Nordin, S; Kozor, R; Moon, J; Bembi, B; Geberhiwot, T; Steeds, R P (2019 թ․ հունվարի 1). «Diagnosis and treatment of the cardiovascular consequences of Fabry disease». QJM: An International Journal of Medicine (անգլերեն). 112 (1): 3–9. doi:10.1093/qjmed/hcy120. ISSN 1460-2725. PMID 29878206.
Wanner, Christoph; Arad, Michael; Baron, Ralf; Burlina, Alessandro; Elliott, Perry M.; Feldt-Rasmussen, Ulla; Fomin, Victor V.; Germain, Dominique P.; Hughes, Derralynn A. (June 2018). «European expert consensus statement on therapeutic goals in Fabry disease» (PDF). Molecular Genetics and Metabolism. 124 (3): 189–203. doi:10.1016/j.ymgme.2018.06.004. ISSN 1096-7206. PMID 30017653. S2CID 51676692.
Keating, Gillian M. (October 2012). «Agalsidase alfa: a review of its use in the management of Fabry disease». BioDrugs. 26 (5): 335–354. doi:10.2165/11209690-000000000-00000. PMID 22946754.
Arends, Maarten; Biegstraaten, Marieke; Wanner, Christoph; Sirrs, Sandra; Mehta, Atul; Elliott, Perry M.; Oder, Daniel; Watkinson, Oliver T.; Bichet, Daniel G.; Khan, Aneal; Iwanochko, Mark; Vaz, Frédéric M.; Van Kuilenburg, André B P.; West, Michael L.; Hughes, Derralynn A.; Hollak, Carla E M. (2018). «Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study». Journal of Medical Genetics. 55 (5): 351–358. doi:10.1136/jmedgenet-2017-104863. PMC 5931248. PMID 29437868.
Turner, Neil N; Turner, Neil N; Lameire, Norbert; Goldsmith, David J; Winearls, Christopher G; Himmelfarb, Jonathan; Remuzzi, Giuseppe, eds. (2015). Fabry disease: Management and outcome. Vol. 1. Oxford University Press. doi:10.1093/med/9780199592548.003.0338. ISBN 9780199592548.
Hughes, D. A.; և այլք: (2017). «Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study». Journal of Medical Genetics. 54 (4): 288–296. doi:10.1136/jmedgenet-2016-104178. PMC 5502308. PMID 27834756.
Ter Huurne, Menno; Parker, Benjamin L.; Liu, Ning Qing; Qian, Elizabeth Ling; Vivien, Celine; Karavendzas, Kathy; Mills, Richard J.; Saville, Jennifer T.; Abu-Bonsrah, Dad; Wise, Andrea F.; Hudson, James E.; Talbot, Andrew S.; Finn, Patrick F.; Martini, Paolo G. V.; Fuller, Maria (2023 թ․ սեպտեմբերի 7). «GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals». American Journal of Human Genetics. 110 (9): 1600–1605. doi:10.1016/j.ajhg.2023.07.013. hdl:2440/139761. ISSN 1537-6605. PMID 37607539.
Waldek, Stephen; Patel, Manesh R.; Banikazemi, Maryam; Lemay, Roberta; Lee, Philip (November 2009). «Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry». Genetics in Medicine. 11 (11): 790–796. doi:10.1097/GIM.0b013e3181bb05bb. PMID 19745746.
Anderson, William (April 1898). «A Case of 'Angeio-Keratoma'». British Journal of Dermatology. 10 (4): 113–117. doi:10.1111/j.1365-2133.1898.tb16317.x. S2CID 70966125.

drugs.com

«Replagal FDA Approval Status». Վերցված է 2022 թ․ մարտի 21-ին.

escholarship.org

Karen, Julie K.; Hale, Elizabeth K.; Ma, Linglei (2005). «Angiokeratoma corporis diffusum (Fabry disease)». Dermatology Online Journal. 11 (4): 8. doi:10.5070/D30TT696NJ. PMID 16403380.

eurekalert.org

«Canada launches first gene therapy trial for Fabry disease». EurekAlert!. Վերցված է 2020 թ․ մայիսի 31-ին.

europa.eu

ema.europa.eu

«Replagal EPAR». 2018 թ․ սեպտեմբերի 17. Վերցված է 2022 թ․ մարտի 21-ին.
«Fabrazyme EPAR». 2018 թ․ սեպտեմբերի 17. Վերցված է 2022 թ․ մարտի 21-ին.
«Elfabrio EPAR». European Medicines Agency. 2023 թ․ մայիսի 8. Վերցված է 2023 թ․ մայիսի 9-ին. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
«Summary of Product Characteristics for Galafold» (PDF). European Medicines Agency. June 2016. Արխիվացված է օրիգինալից (PDF) 2018 թ․ ապրիլի 22-ին. Վերցված է 2024 թ․ հունվարի 27-ին.
«Galafold EPAR». European Medicines Agency (EMA). 2018 թ․ սեպտեմբերի 17. Վերցված է 2020 թ․ սեպտեմբերի 16-ին.
«EU/3/06/368». European Medicines Agency (EMA). 2018 թ․ սեպտեմբերի 17. Վերցված է 2020 թ․ սեպտեմբերի 16-ին.

fabrydisease.org

«You are being redirected...». www.fabrydisease.org. Վերցված է 2019 թ․ դեկտեմբերի 13-ին.
«Fabry Disease Treatment». www.fabrydisease.org. Վերցված է 2022 թ․ մարտի 21-ին.

fabrydiseasenews.com

«Venglustat (Ibiglustat)». Վերցված է 2022 թ․ մարտի 21-ին.

fda.gov

accessdata.fda.gov

«Drug Approval Package: Fabrazyme (agalsidase beta)». www.fda.gov. Վերցված է 2022 թ․ մարտի 21-ին.
«Drug Approval Package: Galafold (migalastat)». www.fda.gov. Վերցված է 2022 թ․ մարտի 21-ին.
«Migalastat Orphan Drug Designations and Approvals». U.S. Food and Drug Administration (FDA). Վերցված է 2020 թ․ սեպտեմբերի 16-ին.

fiercebiotech.com

«Shire Submits Biologics License Application (BLA) for Replagal with the U.S. Food and Drug Administration (FDA)». FierceBiotech. 2009 թ․ դեկտեմբերի 22.

globenewswire.com

«Amicus Therapeutics Announces European Commission Approval for Galafold (Migalastat) in Patients with Fabry Disease in European Union». GlobeNewswire. 2016 թ․ մայիսի 31.

handle.net

hdl.handle.net

Ter Huurne, Menno; Parker, Benjamin L.; Liu, Ning Qing; Qian, Elizabeth Ling; Vivien, Celine; Karavendzas, Kathy; Mills, Richard J.; Saville, Jennifer T.; Abu-Bonsrah, Dad; Wise, Andrea F.; Hudson, James E.; Talbot, Andrew S.; Finn, Patrick F.; Martini, Paolo G. V.; Fuller, Maria (2023 թ․ սեպտեմբերի 7). «GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals». American Journal of Human Genetics. 110 (9): 1600–1605. doi:10.1016/j.ajhg.2023.07.013. hdl:2440/139761. ISSN 1537-6605. PMID 37607539.

harvard.edu

ui.adsabs.harvard.edu

Šimčíková D, Heneberg P (December 2019). «Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases». Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC 6901466. PMID 31819097.

nih.gov

pubmed.ncbi.nlm.nih.gov

Schiffmann, Raphael (2015). «Fabry disease». Neurocutaneous Syndromes. Handbook of Clinical Neurology. Vol. 132. էջեր 231–248. doi:10.1016/B978-0-444-62702-5.00017-2. ISBN 9780444627025. PMID 26564084.
Hoffmann, Bjoern; Beck, Michael; Sunder-Plassmann, Gere; Borsini, Walter; Ricci, Roberta; Mehta, Atul; FOS European, Investigators. (July 2007). «Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey». The Clinical Journal of Pain. 23 (6): 535–542. doi:10.1097/AJP.0b013e318074c986. PMID 17575495. S2CID 36215895.
Putko, Brendan N.; Wen, Kevin; Thompson, Richard B.; Mullen, John; Shanks, Miriam; Yogasundaram, Haran; Sergi, Consolato; Oudit, Gavin Y. (March 2015). «Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment». Heart Failure Reviews. 20 (2): 179–191. doi:10.1007/s10741-014-9452-9. ISSN 1573-7322. PMID 25030479. S2CID 11521278.
Akhtar, M. M.; Elliott, P. M. (2018 թ․ հունիսի 16). «Anderson-Fabry disease in heart failure». Biophysical Reviews. 10 (4): 1107–1119. doi:10.1007/s12551-018-0432-5. ISSN 1867-2450. PMC 6082315. PMID 29909504.
Chew, E.; Ghosh, M.; McCulloch, C. (June 1982). «Amiodarone-induced cornea verticillata». Canadian Journal of Ophthalmology. 17 (3): 96–99. PMID 7116220.
Karen, Julie K.; Hale, Elizabeth K.; Ma, Linglei (2005). «Angiokeratoma corporis diffusum (Fabry disease)». Dermatology Online Journal. 11 (4): 8. doi:10.5070/D30TT696NJ. PMID 16403380.
Šimčíková D, Heneberg P (December 2019). «Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases». Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC 6901466. PMID 31819097.
Perrot, Andreas; Osterziel, Karl Josef; Beck, Michael; Dietz, Rainer; Kampmann, Christoph (2002 թ․ նոյեմբերի 1). «Fabry Disease: Focus on Cardiac Manifestations and Molecular Mechanisms». Herz. 27 (7): 699–702. doi:10.1007/s00059-002-2429-9. PMID 12439642. S2CID 25962218.
Germain, Dominique P (2010). «Fabry disease». Orphanet Journal of Rare Diseases. 5 (1): 30. doi:10.1186/1750-1172-5-30. PMC 3009617. PMID 21092187.
Marchesoni, Cintia L.; Roa, Norma; Pardal, Ana María; Neumann, Pablo; Cáceres, Guillermo; Martínez, Pablo; Kisinovsky, Isaac; Bianchi, Silvia; Tarabuso, Ana Lía; Reisin, Ricardo C. (May 2010). «Misdiagnosis in Fabry disease». The Journal of Pediatrics. 156 (5): 828–31. doi:10.1016/j.jpeds.2010.02.012. PMID 20385321.
Hagège, Albert; Réant, Patricia; Habib, Gilbert; Damy, Thibaud; Barone-Rochette, Gilles; Soulat, Gilles; Donal, Erwan; Germain, Dominique P. (April 2019). «Fabry disease in cardiology practice: Literature review and expert point of view». Archives of Cardiovascular Diseases (անգլերեն). 112 (4): 278–287. doi:10.1016/j.acvd.2019.01.002. PMID 30826269.
Baig, S; Vijapurapu, R; Alharbi, F; Nordin, S; Kozor, R; Moon, J; Bembi, B; Geberhiwot, T; Steeds, R P (2019 թ․ հունվարի 1). «Diagnosis and treatment of the cardiovascular consequences of Fabry disease». QJM: An International Journal of Medicine (անգլերեն). 112 (1): 3–9. doi:10.1093/qjmed/hcy120. ISSN 1460-2725. PMID 29878206.
Wanner, Christoph; Arad, Michael; Baron, Ralf; Burlina, Alessandro; Elliott, Perry M.; Feldt-Rasmussen, Ulla; Fomin, Victor V.; Germain, Dominique P.; Hughes, Derralynn A. (June 2018). «European expert consensus statement on therapeutic goals in Fabry disease» (PDF). Molecular Genetics and Metabolism. 124 (3): 189–203. doi:10.1016/j.ymgme.2018.06.004. ISSN 1096-7206. PMID 30017653. S2CID 51676692.
Keating, Gillian M. (October 2012). «Agalsidase alfa: a review of its use in the management of Fabry disease». BioDrugs. 26 (5): 335–354. doi:10.2165/11209690-000000000-00000. PMID 22946754.
Arends, Maarten; Biegstraaten, Marieke; Wanner, Christoph; Sirrs, Sandra; Mehta, Atul; Elliott, Perry M.; Oder, Daniel; Watkinson, Oliver T.; Bichet, Daniel G.; Khan, Aneal; Iwanochko, Mark; Vaz, Frédéric M.; Van Kuilenburg, André B P.; West, Michael L.; Hughes, Derralynn A.; Hollak, Carla E M. (2018). «Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study». Journal of Medical Genetics. 55 (5): 351–358. doi:10.1136/jmedgenet-2017-104863. PMC 5931248. PMID 29437868.
Hughes, D. A.; և այլք: (2017). «Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study». Journal of Medical Genetics. 54 (4): 288–296. doi:10.1136/jmedgenet-2016-104178. PMC 5502308. PMID 27834756.
Ter Huurne, Menno; Parker, Benjamin L.; Liu, Ning Qing; Qian, Elizabeth Ling; Vivien, Celine; Karavendzas, Kathy; Mills, Richard J.; Saville, Jennifer T.; Abu-Bonsrah, Dad; Wise, Andrea F.; Hudson, James E.; Talbot, Andrew S.; Finn, Patrick F.; Martini, Paolo G. V.; Fuller, Maria (2023 թ․ սեպտեմբերի 7). «GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals». American Journal of Human Genetics. 110 (9): 1600–1605. doi:10.1016/j.ajhg.2023.07.013. hdl:2440/139761. ISSN 1537-6605. PMID 37607539.
Waldek, Stephen; Patel, Manesh R.; Banikazemi, Maryam; Lemay, Roberta; Lee, Philip (November 2009). «Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry». Genetics in Medicine. 11 (11): 790–796. doi:10.1097/GIM.0b013e3181bb05bb. PMID 19745746.
Mehta, Atul; Beck, Michael; Linhart, Aleš; Sunder-Plassmann, Gere; Widmer, Urs (2006), Mehta, Atul; Beck, Michael; Sunder-Plassmann, Gere (eds.), «History of lysosomal storage diseases: an overview», Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis, ISBN 978-1903539033, PMID 21290707, Վերցված է 10 August 2018-ին

ncbi.nlm.nih.gov

Akhtar, M. M.; Elliott, P. M. (2018 թ․ հունիսի 16). «Anderson-Fabry disease in heart failure». Biophysical Reviews. 10 (4): 1107–1119. doi:10.1007/s12551-018-0432-5. ISSN 1867-2450. PMC 6082315. PMID 29909504.
«Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two». Pediatric Rheumatology Online Journal. 15 (Suppl 2): 65. 2017 թ․ սեպտեմբերի 1. doi:10.1186/s12969-017-0186-9. PMC 5592437.
Šimčíková D, Heneberg P (December 2019). «Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases». Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC 6901466. PMID 31819097.
Germain, Dominique P (2010). «Fabry disease». Orphanet Journal of Rare Diseases. 5 (1): 30. doi:10.1186/1750-1172-5-30. PMC 3009617. PMID 21092187.
Arends, Maarten; Biegstraaten, Marieke; Wanner, Christoph; Sirrs, Sandra; Mehta, Atul; Elliott, Perry M.; Oder, Daniel; Watkinson, Oliver T.; Bichet, Daniel G.; Khan, Aneal; Iwanochko, Mark; Vaz, Frédéric M.; Van Kuilenburg, André B P.; West, Michael L.; Hughes, Derralynn A.; Hollak, Carla E M. (2018). «Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: An international cohort study». Journal of Medical Genetics. 55 (5): 351–358. doi:10.1136/jmedgenet-2017-104863. PMC 5931248. PMID 29437868.
Hughes, D. A.; և այլք: (2017). «Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study». Journal of Medical Genetics. 54 (4): 288–296. doi:10.1136/jmedgenet-2016-104178. PMC 5502308. PMID 27834756.
Mehta, Atul; Beck, Michael; Linhart, Aleš; Sunder-Plassmann, Gere; Widmer, Urs (2006), Mehta, Atul; Beck, Michael; Sunder-Plassmann, Gere (eds.), «History of lysosomal storage diseases: an overview», Fabry Disease: Perspectives from 5 Years of FOS, Oxford PharmaGenesis, ISBN 978-1903539033, PMID 21290707, Վերցված է 10 August 2018-ին

rarediseases.info.nih.gov

«Fabry disease | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program». rarediseases.info.nih.gov (անգլերեն). Վերցված է 2018 թ․ ապրիլի 17-ին.

npr.org

«With A Life-Saving Medicine In Short Supply, Patients Want Patent Broken». NPR.org. 2010 թ․ օգոստոսի 4. Արխիվացված օրիգինալից 14 September 2010-ին. Վերցված է 2010 թ․ սեպտեմբերի 2-ին.

oup.com

academic.oup.com

Baig, S; Vijapurapu, R; Alharbi, F; Nordin, S; Kozor, R; Moon, J; Bembi, B; Geberhiwot, T; Steeds, R P (2019 թ․ հունվարի 1). «Diagnosis and treatment of the cardiovascular consequences of Fabry disease». QJM: An International Journal of Medicine (անգլերեն). 112 (1): 3–9. doi:10.1093/qjmed/hcy120. ISSN 1460-2725. PMID 29878206.

oxfordmedicine.com

Turner, Neil N; Turner, Neil N; Lameire, Norbert; Goldsmith, David J; Winearls, Christopher G; Himmelfarb, Jonathan; Remuzzi, Giuseppe, eds. (2015). Fabry disease: Management and outcome. Vol. 1. Oxford University Press. doi:10.1093/med/9780199592548.003.0338. ISBN 9780199592548.

pharmatimes.com

Grogan, K. (2012 թ․ մարտի 15). «Shire withdraws Replagal in USA as FDA wants more trials». PharmaTimes. Արխիվացված է օրիգինալից 2014 թ․ օգոստոսի 19-ին.

semanticscholar.org

api.semanticscholar.org

Fabry, Joh (December 1898). «Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)» [A contribution to the knowledge of the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Archiv für Dermatologie und Syphilis (գերմաներեն). 43 (1): 187–200. doi:10.1007/bf01986897. S2CID 33956139.
Hoffmann, Bjoern; Beck, Michael; Sunder-Plassmann, Gere; Borsini, Walter; Ricci, Roberta; Mehta, Atul; FOS European, Investigators. (July 2007). «Nature and Prevalence of Pain in Fabry Disease and Its Response to Enzyme Replacement Therapy—A Retrospective Analysis From the Fabry Outcome Survey». The Clinical Journal of Pain. 23 (6): 535–542. doi:10.1097/AJP.0b013e318074c986. PMID 17575495. S2CID 36215895.
Putko, Brendan N.; Wen, Kevin; Thompson, Richard B.; Mullen, John; Shanks, Miriam; Yogasundaram, Haran; Sergi, Consolato; Oudit, Gavin Y. (March 2015). «Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment». Heart Failure Reviews. 20 (2): 179–191. doi:10.1007/s10741-014-9452-9. ISSN 1573-7322. PMID 25030479. S2CID 11521278.
Perrot, Andreas; Osterziel, Karl Josef; Beck, Michael; Dietz, Rainer; Kampmann, Christoph (2002 թ․ նոյեմբերի 1). «Fabry Disease: Focus on Cardiac Manifestations and Molecular Mechanisms». Herz. 27 (7): 699–702. doi:10.1007/s00059-002-2429-9. PMID 12439642. S2CID 25962218.
Wanner, Christoph; Arad, Michael; Baron, Ralf; Burlina, Alessandro; Elliott, Perry M.; Feldt-Rasmussen, Ulla; Fomin, Victor V.; Germain, Dominique P.; Hughes, Derralynn A. (June 2018). «European expert consensus statement on therapeutic goals in Fabry disease» (PDF). Molecular Genetics and Metabolism. 124 (3): 189–203. doi:10.1016/j.ymgme.2018.06.004. ISSN 1096-7206. PMID 30017653. S2CID 51676692.
Anderson, William (April 1898). «A Case of 'Angeio-Keratoma'». British Journal of Dermatology. 10 (4): 113–117. doi:10.1111/j.1365-2133.1898.tb16317.x. S2CID 70966125.

ucl.ac.uk

discovery.ucl.ac.uk

Wanner, Christoph; Arad, Michael; Baron, Ralf; Burlina, Alessandro; Elliott, Perry M.; Feldt-Rasmussen, Ulla; Fomin, Victor V.; Germain, Dominique P.; Hughes, Derralynn A. (June 2018). «European expert consensus statement on therapeutic goals in Fabry disease» (PDF). Molecular Genetics and Metabolism. 124 (3): 189–203. doi:10.1016/j.ymgme.2018.06.004. ISSN 1096-7206. PMID 30017653. S2CID 51676692.

uhnresearch.ca

tdc.uhnresearch.ca

«UHN Start-up AVROBIO, Inc. Announces $60 Million Series B Financing to Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic Diseases | TDC».

web.archive.org

«With A Life-Saving Medicine In Short Supply, Patients Want Patent Broken». NPR.org. 2010 թ․ օգոստոսի 4. Արխիվացված օրիգինալից 14 September 2010-ին. Վերցված է 2010 թ․ սեպտեմբերի 2-ին.
Grogan, K. (2012 թ․ մարտի 15). «Shire withdraws Replagal in USA as FDA wants more trials». PharmaTimes. Արխիվացված է օրիգինալից 2014 թ․ օգոստոսի 19-ին.
«Summary of Product Characteristics for Galafold» (PDF). European Medicines Agency. June 2016. Արխիվացված է օրիգինալից (PDF) 2018 թ․ ապրիլի 22-ին. Վերցված է 2024 թ․ հունվարի 27-ին.

worldcat.org

Putko, Brendan N.; Wen, Kevin; Thompson, Richard B.; Mullen, John; Shanks, Miriam; Yogasundaram, Haran; Sergi, Consolato; Oudit, Gavin Y. (March 2015). «Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment». Heart Failure Reviews. 20 (2): 179–191. doi:10.1007/s10741-014-9452-9. ISSN 1573-7322. PMID 25030479. S2CID 11521278.
Akhtar, M. M.; Elliott, P. M. (2018 թ․ հունիսի 16). «Anderson-Fabry disease in heart failure». Biophysical Reviews. 10 (4): 1107–1119. doi:10.1007/s12551-018-0432-5. ISSN 1867-2450. PMC 6082315. PMID 29909504.
Baig, S; Vijapurapu, R; Alharbi, F; Nordin, S; Kozor, R; Moon, J; Bembi, B; Geberhiwot, T; Steeds, R P (2019 թ․ հունվարի 1). «Diagnosis and treatment of the cardiovascular consequences of Fabry disease». QJM: An International Journal of Medicine (անգլերեն). 112 (1): 3–9. doi:10.1093/qjmed/hcy120. ISSN 1460-2725. PMID 29878206.
Wanner, Christoph; Arad, Michael; Baron, Ralf; Burlina, Alessandro; Elliott, Perry M.; Feldt-Rasmussen, Ulla; Fomin, Victor V.; Germain, Dominique P.; Hughes, Derralynn A. (June 2018). «European expert consensus statement on therapeutic goals in Fabry disease» (PDF). Molecular Genetics and Metabolism. 124 (3): 189–203. doi:10.1016/j.ymgme.2018.06.004. ISSN 1096-7206. PMID 30017653. S2CID 51676692.
Ter Huurne, Menno; Parker, Benjamin L.; Liu, Ning Qing; Qian, Elizabeth Ling; Vivien, Celine; Karavendzas, Kathy; Mills, Richard J.; Saville, Jennifer T.; Abu-Bonsrah, Dad; Wise, Andrea F.; Hudson, James E.; Talbot, Andrew S.; Finn, Patrick F.; Martini, Paolo G. V.; Fuller, Maria (2023 թ․ սեպտեմբերի 7). «GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals». American Journal of Human Genetics. 110 (9): 1600–1605. doi:10.1016/j.ajhg.2023.07.013. hdl:2440/139761. ISSN 1537-6605. PMID 37607539.

zenodo.org

Fabry, Joh (December 1898). «Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae)» [A contribution to the knowledge of the purpura haemorrhagica nodularis (purpura papulosa haemorrhagica Hebrae)]. Archiv für Dermatologie und Syphilis (գերմաներեն). 43 (1): 187–200. doi:10.1007/bf01986897. S2CID 33956139.
Anderson, William (April 1898). «A Case of 'Angeio-Keratoma'». British Journal of Dermatology. 10 (4): 113–117. doi:10.1111/j.1365-2133.1898.tb16317.x. S2CID 70966125.